Expand all sections

Pomalidomide

Extended indication Treatment of adult patients with relapsed and refractory multiple myeloma in combination with dexame
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Pomalidomide
Domain Hematology
Reason of inclusion Generic
Main indication Multiple Myeloma
Extended indication Treatment of adult patients with relapsed and refractory multiple myeloma in combination with dexamethasone
Current proprietary name Imnovid
Mechanism of action Immunosuppression
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)
Additional remarks Immuunmodulator/proteasoom inhibitor. Fabrikant Celgene

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date March 2023
Expected Registration April 2024
Orphan drug Yes
Registration phase Registration application pending
Additional remarks Marktexclusiviteit verloopt op 8 augustus 2023

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.